Comparison of the hematological effects of a sustained release chitosan formulation of pentoxifylline with a commercial formulation


Yamac K., Kaptan K., Beyan C., Teksin Z. Ş. , Agabeyoglu I., Gokgoz L.

ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH, vol.50, no.9, pp.827-831, 2000 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 50 Issue: 9
  • Publication Date: 2000
  • Doi Number: 10.1055/s-0031-1300296
  • Journal Name: ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.827-831
  • Gazi University Affiliated: Yes

Abstract

In the present study the hematological effects of a sustained release chitosan formulation of pentoxifylline (CAS 6493-05-6) were examined and compared with those of a commercial product. The study was carried out on 12 healthy volunteers. Both formulations were tolerated well clinically. The results demonstrated no antiaggregatory effect of the two different formulations of pentoxifylline in platelet rich plasma. Both drugs resulted in a decrease of plasma fibrinogen levels. A remarkable side effect of the new formulation was mild basophilia, without any clinical problems.